A placebo-controlled, group sequential, adaptive treatment assignment study of intravenous COL-144 (LY573144) in the acute treatment of migraine

Trial Profile

A placebo-controlled, group sequential, adaptive treatment assignment study of intravenous COL-144 (LY573144) in the acute treatment of migraine

Completed
Phase of Trial: Phase II

Latest Information Update: 03 Jun 2015

At a glance

  • Drugs Lasmiditan (Primary)
  • Indications Migraine with aura; Migraine without aura
  • Focus Therapeutic Use
  • Sponsors CoLucid Pharmaceuticals
  • Most Recent Events

    • 01 Oct 2010 Results published in Cephalalgia.
    • 18 Sep 2007 Status changed from recruiting to completed.
    • 22 Nov 2006 Status change
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top